Citations

Clear

8 citation(s) found for "Schols, AM".

The ILLUMINATE natural history study in colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
Wade, Charles, Hayer, Stefanie N, Gelfand, Jeffrey M, Köhler, Wolfgang , Bergner, Christa-Caroline, Souza, Paulo Victor Sgobbi de, Finger, Elizabeth , Wolf, Nicole I. , Orthmann-Murphy, Jennifer L, Chmiela, Tomasz, Rajagovindan, Raj, McLaren, Donald G, Gaudreault, Francois, Mirescu, Christian, Raitcheva, Denitza, Meier, Andreas, Gray, David, Chavez, Juan, Kaufmann, Petra, Wszolek, Zbigniew K, Chmiela, Tomasz , Lynch, David S , Schöls, Ludger , Köhler, Wolfgang , Finger, Elizabeth C. , Wolf, Nicole I , Beerepoot, Shanice , Chmiela, Tomasz , Wade, Charles , Hayer, Stefanie N. , Gelfand, Jeffrey M. , Bergner, Caroline, Souza, Paulo Victor Sgobbi de , Orthmann‐Murphy, Jennifer , Rajagovindan, Raj, McLaren, Donald G. , Mirescu, Christian, Raitcheva, Denitza , Meier, Andreas , Kaufmann, Petra, Wszołek, Zbigniew K.

Mayo Clinic

Brain Communications | July 11, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcag271 | PMID 42500553 Get It

Abstract Colony-stimulating factor 1 receptor-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (CSF1R-ALSP) is a rare, fatal, autosomal-dominant neurodegenerative disorder caused by pathogenic CSF1R variants and characterized by progressive cognitive, neuropsychiatric, and motor dysfunction, white matter lesions on brain imaging, and white matter demyelination, swollen axons, and pigmented glial cells on pathology. Limited data regarding clinical, biofluid or radiological biomarkers of disease severity are available, and no clinical trial endpoints have yet been validated. The objectives of this first-of-its-kind, prospective, observational natural history study were to characterize the clinical trajectory of CSF1R-ALSP and to identify and evaluate key biomarkers and clinical endpoints indicative of disease severity and progression. ILLUMINATE (NCT05020743) was a multicentre, noninterventional natural history study of adults with CSF1R-ALSP and prodromal carriers of CSF1R variants. Participants were followed for up to 36 months, with clinical assessments, fluid biomarkers and volumetric MRI assessments of brain atrophy collected at screening and every 6 months. This study was terminated early (4 June 2025). The analyses reported here include data collected through 19 February 2025. Of 53 participants, 19 were prodromal and 34 were symptomatic (11 of whom had a history of haematopoietic stem cell transplant and 23 who did not). Mean participant age was 47.8 (standard deviation, 4.5) years, and 36.4% were female. Prodromal participants remained relatively stable over 36 months, with little change in neurological function, neurodegeneration biomarkers or radiological disease burden. Impaired neurological function, MRI characteristics of CSF1R-ALSP, and elevated NfL (neurofilament light chain; neurodegeneration biomarker) and GFAP (glial fibrillary acidic protein; astrogliosis biomarker) levels were more pronounced at baseline and often showed progression over time among symptomatic participants who had not previously received haematopoietic stem cell transplant compared with participants who had previously received haematopoietic stem cell transplant. Significant correlations were observed at baseline and longitudinally between MRI measures of brain atrophy and clinical outcome measures. Based on the fluid biomarkers, MRI measures, and clinical outcome assessments evaluated here, active neurodegeneration, widespread changes visualized on brain MRI, and impaired cognitive and motor function were observed in symptomatic patients with CSF1R-ALSP. The neurological impairment can be assessed using the Montreal Cognitive Assessment and Cortical Basal ganglia Functional Scale. Our data suggest that quantification of brain atrophy using MRI volumetry is a potential biomarker of disease severity and progression in CSF1R-ALSP. It is hoped that this report will contribute to the understanding of disease progression in CSF1R-ALSP and inform future drug development.
Brain Volume Loss Correlation with Clinical Severity and Progression in Individuals with CSF1R-ALSP: Findings from the ILLUMINATE Prospective Natural History Study (P4-3.017)
Koehler, Wolfgang, Bergner, Caroline, Hayer, Stefanie N. , Murphy, Jennifer Orthmann, Meier, Andreas , Doros, Gheorghe , Rajagovindan, Rajasimhan, Kaufmann, Petra, Lynch, David R. , Gelfand, Jeffrey M. , Wolf, Nicole I , Schöls, Ludger , Finger, Elizabeth C. , Meier, Andreas, Wade, Charles , McLaren, Donald G. , Rajagovindan, Raj, Wszołek, Zbigniew K.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000208880 Get It

Findings from the ILLUMINATE Prospective Natural History Study (NHS) in Individuals with Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (P3-9.001)
Koehler, Wolfgang, Bergner, Caroline, Hayer, Stefanie N. , Murphy, Jennifer Orthmann, Matys, Benjamin, Meier, Andreas , Rajagovindan, Rajasimhan, Gelfand, Jeffrey M. , Lynch, David S , Wade, Charles , Wolf, Nicole I , Schöls, Ludger , Finger, Elizabeth C. , Papapetropoulos, Spyridon , McLaren, Donald G. , Meier, Andreas, Rajagovindan, Raj, Wszołek, Zbigniew K.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205286 Get It

A Prospective Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (S49.008)
Rajagovindan, Raj, Matys, Benjamin, Köhler, Wolfgang, Lynch, David A. , Orthmann‐Murphy, Jennifer , Meier, Andreas , Papapetropoulos, Spyridon , Wszolek, Zbigniew, Papapetropoulos, Spyros , Finger, Elizabeth C. , Gelfand, Jeffrey M. , Isaacson, Stuart , Kumar, Rajeev, Schöls, Ludger , Wolf, Nicole I , Meier, Andreas, Wszołek, Zbigniew K.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203073 Get It

Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3
García‐Moreno, Héctor , Prudencio, Mercedes , Thomas‐Black, Gilbert , Solanky, Nita , Jansen‐West, Karen , Al‐Shaikh, Rana Hanna , Heslegrave, Amanda , Zetterberg, Henrik , Santana, Magda M. , Almeida, Luís Pereira de , Vasconcelos‐Ferreira, Ana , Infante, Jon , Faber, Jennifer , Klockgether, Thomas , Reetz, Kathrin , Raposo, Mafalda , Ferreira, Ana F. , Lima, Manuela , Schöls, Lüdger , Synofzik, Matthis , Hübener‐Schmid, Jeannette , Puschmann, Andreas , Gorcenco, Sorina , Petrucelli, Leonard , Jansen-West, Karen R , Hanna Al-Shaikh, Rana , Pereira de Almeida, Luis , Infante, Jon , Reetz, Kathrin , Raposo, Mafalda , Lima, Manuela , Schöls, Ludger , Synofzik, Matthis , Hübener-Schmid, Jeannette , Puschmann, Andreas , Gorcenco, Sorina , Wszolek, Z.K. , Petrucelli, Leonard , Giunti, Paola , Prudencio, Mercedes , Zetterberg, Henrik , Januário, Cristina , Wszołek, Zbigniew K.

Mayo Clinic

European Journal of Neurology | April 28, 2022 | Volume: 29 | Issue: 8 | Pages: 2439-2452

10.1111/ene.15373 | PMID 35478426 Get It

AbstractBackground and purposeClinical trials in spinocerebellar ataxia type 3 (SCA3) will require biomarkers for use as outcome measures.MethodsTo evaluate total tau (t‐tau), glial fibrillary acidic protein (GFAP), ubiquitin carboxy‐terminal hydrolase L1 (UCHL1) and neurofilament light‐chain (NfL) as fluid biomarkers in SCA3, ATXN3 mutation carriers (n = 143) and controls (n = 172) were clinically assessed, and the plasma concentrations of the four proteins were analysed on the Simoa HD‐1 platform. Eleven ATXN3 mutation carrier cerebrospinal fluid samples were analysed for t‐tau and phosphorylated tau (p‐tau181). A transgenic SCA3 mouse model (MJDTg) was used to measure cerebellar t‐tau levels.ResultsPlasma t‐tau levels were higher in mutation carriers below the age of 50 compared to controls, and the Inventory of Non‐Ataxia Signs was associated with t‐tau in ataxic patients (p = 0.004). Pre‐ataxic carriers showed higher cerebrospinal fluid t‐tau and p‐tau181 concentrations compared to ataxic patients (p = 0.025 and p = 0.014, respectively). Cerebellar t‐tau was elevated in MJDTg mice compared to wild‐type (p = 0.033) only in the early stages of the disease. GFAP and UCHL1 did not show higher levels in mutation carriers compared to controls. Plasma NfL concentrations were higher in mutation carriers compared to controls, and differences were greater for younger carriers. The Scale for the Assessment and Rating of Ataxia was the strongest predictor of NfL in ataxic patients (p < 0.001).ConclusionOur results suggest that tau might be a marker of early disease stages in SCA3. NfL can discriminate mutation carriers from controls and is associated with different clinical variables. Longitudinal studies are required to confirm their potential role as biomarkers in clinical trials.
Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo‐controlled randomized cross‐over clinical trial
Vuren, Annelies J. van , Kerkhoffs, Jean‐Louis , Schols, Saskia E.M. , Rijneveld, Anita W. , Nur, Erfan , Peereboom, Dore, Gandon, Y. , Welsing, Paco M J, Wijk, Richard van , Schutgens, Roger E. G. , Solinge, Wouter W. van , Marx, Joannes J.M., Biemond, Bart J. , van Vuren, Annelies , Schols, Saskia , Gandon, Yves , Welsing, Paco , van Wijk, Richard , Schutgens, Roger , van Solinge, Wouter , Leiner, Tim , Biemond, Bart , van Beers, Eduard , Leiner, Tim , Biemond, Bart J. , Beers, Eduard J. van

Mayo Clinic

American Journal of Hematology | April 26, 2022 | Volume: 97 | Issue: 7 | Pages: 924-932

10.1002/ajh.26581 | PMID 35472008 Get It

AbstractIron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side‐effects, high costs, and the lack of availability in many countries with a high prevalence of hereditary anemias. In this phase III randomized placebo‐controlled trial, we assigned adults with non‐transfusion‐dependent hereditary anemias with mild‐to‐moderate iron overload to receive esomeprazole (at a dose of 40 mg twice daily) or placebo for 12 months in a cross‐over design. The primary end point was change of liver iron content measured by MRI. A total of 30 participants were enrolled in the trial. Treatment with esomeprazole resulted in a statistically significant reduction in liver iron content that was 0.55 mg Fe/g dw larger than after treatment with placebo (95%CI [0.05 to 1.06]; p = 0.03). Median baseline liver iron content at the start of esomeprazole was 4.99 versus 4.49 mg Fe/g dw at start of placebo. Mean delta liver iron content after esomeprazole treatment was −0.57 (SD 1.20) versus −0.11 mg Fe/g dw (SD 0.75) after placebo treatment. Esomeprazole was well tolerated, reported adverse events were mild and none of the patients withdrew from the study due to side effects. In summary, esomeprazole resulted in a significant reduction in liver iron content when compared to placebo in a heterogeneous group of patients with non‐transfusion‐dependent hereditary anemias. From an international perspective this result can have major implications given the fact that proton pump inhibitors may frequently be the only realistic therapy for many patients without access to or not tolerating iron chelators.
Sarcopenia: A Time for Action. An SCWD Position Paper
Bauer, Jürgen M. , Morley, John E. , Schols, Annemie M.W.J. , Ferrucci, Luigi , Cruz‐Jentoft, Alfonso J. , Dent, Elsa , Crawford, Jeffrey A., Doehner, Wolfram , Jatoi, Aminah , Kalantar‐Zadeh, Kamyar, Landi, Francesco , Laviano, Alessandro , Muscaritoli, Maurizio , Prado, Carla M. , Strasser, Florian, Haehling, Stephan von , Kalantar-Zadeh, Kamyar , Ferrucci, Luigi , Baracos, Vickie E. , Heymsfield, Steven B. , Lainščak, Mitja , Mancuso, Michelangelo , Coats, Andrew J.S. , Anker, Stefan D. , Doehner, Wolfram , Kalantar-Zadeh, Kamyar

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | September 16, 2019 | Volume: 10 | Issue: 5 | Pages: 956-961

10.1002/jcsm.12483 | PMID 31523937 Get It

Abstract The term sarcopenia was introduced in 1988. The original definition was a “muscle loss” of the appendicular muscle mass in the older people as measured by dual energy x‐ray absorptiometry (DXA). In 2010, the definition was altered to be low muscle mass together with low muscle function and this was agreed upon as reported in a number of consensus papers. The Society of Sarcopenia, Cachexia and Wasting Disorders supports the recommendations of more recent consensus conferences, i.e. that rapid screening, such as with the SARC‐F questionnaire, should be utilized with a formal diagnosis being made by measuring grip strength or chair stand together with DXA estimation of appendicular muscle mass (indexed for height2). Assessments of the utility of ultrasound and creatine dilution techniques are ongoing. Use of ultrasound may not be easily reproducible. Primary sarcopenia is aging associated (mediated) loss of muscle mass. Secondary sarcopenia (or disease‐related sarcopenia) has predominantly focused on loss of muscle mass without the emphasis on muscle function. Diseases that can cause muscle wasting (i.e. secondary sarcopenia) include malignant cancer, COPD, heart failure, and renal failure and others. Management of sarcopenia should consist of resistance exercise in combination with a protein intake of 1 to 1.5 g/kg/day. There is insufficient evidence that vitamin D and anabolic steroids are beneficial. These recommendations apply to both primary (age‐related) sarcopenia and secondary (disease related) sarcopenia. Secondary sarcopenia also needs appropriate treatment of the underlying disease. It is important that primary care health professionals become aware of and make the diagnosis of age‐related and disease‐related sarcopenia. It is important to address the risk factors for sarcopenia, particularly low physical activity and sedentary behavior in the general population, using a life‐long approach. There is a need for more clinical research into the appropriate measurement for muscle mass and the management of sarcopenia. Accordingly, this position statement provides recommendations on the management of sarcopenia and how to progress the knowledge and recognition of sarcopenia.